RU2013138835A - Гетероциклические соединения в качестве ингибиторов pi3 киназы - Google Patents
Гетероциклические соединения в качестве ингибиторов pi3 киназы Download PDFInfo
- Publication number
- RU2013138835A RU2013138835A RU2013138835/04A RU2013138835A RU2013138835A RU 2013138835 A RU2013138835 A RU 2013138835A RU 2013138835/04 A RU2013138835/04 A RU 2013138835/04A RU 2013138835 A RU2013138835 A RU 2013138835A RU 2013138835 A RU2013138835 A RU 2013138835A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- alkylene
- conh
- dimethyl
- phenyl
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 claims abstract 13
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 13
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 11
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims abstract 10
- -1 1,1-dioxo-thiopyran-4-yl Chemical group 0.000 claims abstract 9
- 125000003118 aryl group Chemical group 0.000 claims abstract 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract 8
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 7
- 125000004452 carbocyclyl group Chemical group 0.000 claims abstract 7
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims abstract 4
- 125000003566 oxetanyl group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 206010061218 Inflammation Diseases 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 208000026278 immune system disease Diseases 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 4
- 208000025966 Neurological disease Diseases 0.000 claims 4
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 4
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 4
- 102000001708 Protein Isoforms Human genes 0.000 claims 4
- 108010029485 Protein Isoforms Proteins 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- 210000000214 mouth Anatomy 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 230000003394 haemopoietic effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 2
- RUMXNOHAGSMYEM-UHFFFAOYSA-N 1-[(3-phenyl-1-benzothiophen-2-yl)methyl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=CC=2C(N)=NC=NC=2N1CC=1SC2=CC=CC=C2C=1C1=CC=CC=C1 RUMXNOHAGSMYEM-UHFFFAOYSA-N 0.000 claims 1
- BYTRPZLYYIPRLJ-UHFFFAOYSA-N 8h-pyrido[2,3-d]pyrimidin-5-one Chemical compound C1=NC=C2C(O)=CC=NC2=N1 BYTRPZLYYIPRLJ-UHFFFAOYSA-N 0.000 claims 1
- QEFKTWBYRWCRFQ-UHFFFAOYSA-N 9-[(3-phenyl-1-benzofuran-2-yl)methyl]purin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1OC2=CC=CC=C2C=1C1=CC=CC=C1 QEFKTWBYRWCRFQ-UHFFFAOYSA-N 0.000 claims 1
- ZQEOHEJDOAVAKQ-UHFFFAOYSA-N 9-[(3-phenyl-1-benzothiophen-2-yl)methyl]purin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1SC2=CC=CC=C2C=1C1=CC=CC=C1 ZQEOHEJDOAVAKQ-UHFFFAOYSA-N 0.000 claims 1
- VWSBHWDUOAGEGI-UHFFFAOYSA-N 9-[(3-phenyl-1h-indol-2-yl)methyl]purin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1CC=1NC2=CC=CC=C2C=1C1=CC=CC=C1 VWSBHWDUOAGEGI-UHFFFAOYSA-N 0.000 claims 1
- VGMHTMGUYJNOTR-UHFFFAOYSA-N 9-[[3-(2-methylphenyl)-1-benzothiophen-2-yl]methyl]purin-6-amine Chemical compound CC1=CC=CC=C1C(C1=CC=CC=C1S1)=C1CN1C2=NC=NC(N)=C2N=C1 VGMHTMGUYJNOTR-UHFFFAOYSA-N 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 229960000643 adenine Drugs 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 231100000507 endocrine disrupting Toxicity 0.000 claims 1
- 230000007368 endocrine function Effects 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000000088 lip Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000001989 nasopharynx Anatomy 0.000 claims 1
- 239000003076 neurotropic agent Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 210000004197 pelvis Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004928 piperidonyl group Chemical group 0.000 claims 1
- TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000010174 renal carcinoma Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030829 thyroid gland adenocarcinoma Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
и его стереоизомеры, геометрические изомеры, таутомеры и фармацевтически приемлемые соли, где:Zпредставляет собой CRили N;Zпредставляет собой CRили N;Zпредставляет собой CRили N;Zпредставляет собой CRили N;где ни одного, один или два из Z, Z, Zи Zили N;где (i) Xпредставляет собой NR, и Xпредставляет собой N, (ii) Xпредставляет собой S, и Xпредставляет собой CR, (iii) Xпредставляет собой О, и Xпредставляет собой CR, или (iv) Xпредставляет собой NR, и Xпредставляет собой CR;Rвыбран из Н, C-Cалкила, С-Салкенила и С-Салкинила, где алкил, алкенил и алкинил возможно замещены одной или более группами, независимо выбранными из F, Cl, Br, I, -CN, -СОН, -СОСН, -СОС(СН), -СОСН, -CONH, -CONHCH, -CON(СН), -NO, -NH, -NHCH, -N(СН), -NHCOCH, -NHS(O)СН, -N(СН)С(СН)CONH, -N(СН)CHCHS(O)СН, =O, -ОН, -ОСН, -ОСНСН, -ОСН(СН), -S(O)N(СН), -SCH, и -S(O)СН;R, R, R, R, R, Rи Rнезависимо выбраны из Н, F, Cl, Br, I, -СН, -СНСН, -С(СН), -CHOH, -CHCHOH, -С(СН)OH, -CHOCH, -CN, -CF, -COH, -СОСН, -СОС(СН), -COCH, -CONH, -CONHCH, -CON(СН), -C(CH)CONH, -NO, -NH, -NHCH, -N(СН), -NHCOCH, -NHS(O)СН, -N(СН)С(СН)CONH, -N(СН)CHCHS(O)СН, =O, -ОН, -ОСН, -OCF, -S(O)N(СН), -SCH, -S(O)СН, циклопропила, циклобутила, оксетанила, морфолино и 1,1-диоксо-тиопиран-4-ила;Rи Rобразуют пятичленное или шестичленное гетероарильное или гетероциклическое кольцо, возможно замещенное одной или более группой R;Rпредставляет собой Н, C-Cалкил, С-Салкенил, С-Салкинил, С-Сарил, С-Скарбоциклил, C-Cгетероциклил, C-Cгетероарил, -(C-Cалкилен)-(С-Скарбоциклил), -(C-Cалкилен)-(С-Сгетероциклил), -(C-Cалкилен)-С(=O)-(С-Сгетероциклил), -(C-Cалкилен)-(С-Сарил), -(С-Сарил)-(С-Сгетероарил), -(С-Сарил)-(С-Сгетероциклил), и -(C-Cалкилен)-(С-Сгетероарил), где алкил, алкенил, алкинил, алкилен, карбоциклил, гетероциклил, арил и гетероарил возможно замещены одной или более группами, независимо выбранными из F, Cl, Br, I, -СН, -СНСН, -С(СН), -CHOH, -CHCHOH,
Claims (18)
и его стереоизомеры, геометрические изомеры, таутомеры и фармацевтически приемлемые соли, где:
Z1 представляет собой CR1 или N;
Z2 представляет собой CR2 или N;
Z3 представляет собой CR3 или N;
Z4 представляет собой CR4 или N;
где ни одного, один или два из Z1, Z2, Z3 и Z4 или N;
где (i) X1 представляет собой NR10, и X2 представляет собой N, (ii) X1 представляет собой S, и X2 представляет собой CR11, (iii) X1 представляет собой О, и X2 представляет собой CR11, или (iv) X1 представляет собой NR10, и X2 представляет собой CR11;
R5 выбран из Н, C1-C12 алкила, С2-С8 алкенила и С2-С8 алкинила, где алкил, алкенил и алкинил возможно замещены одной или более группами, независимо выбранными из F, Cl, Br, I, -CN, -СО2Н, -СОСН3, -СОС(СН3)3, -СО2СН3, -CONH2, -CONHCH3, -CON(СН3)2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -NHS(O)2СН3, -N(СН3)С(СН3)2CONH2, -N(СН3)CH2CH2S(O)2СН3, =O, -ОН, -ОСН3, -ОСН2СН3, -ОСН(СН3)2, -S(O)2N(СН3)2, -SCH3, и -S(O)2СН3;
R1, R2, R3, R4, R7, R8 и R12 независимо выбраны из Н, F, Cl, Br, I, -СН3, -СН2СН3, -С(СН3)3, -CH2OH, -CH2CH2OH, -С(СН3)2OH, -CH2OCH3, -CN, -CF3, -CO2H, -СОСН3, -СОС(СН3)3, -CO2CH3, -CONH2, -CONHCH3, -CON(СН3)2, -C(CH3)2CONH2, -NO2, -NH2, -NHCH3, -N(СН3)2, -NHCOCH3, -NHS(O)2СН3, -N(СН3)С(СН3)2CONH2, -N(СН3)CH2CH2S(O)2СН3, =O, -ОН, -ОСН3, -OCF3, -S(O)2N(СН3)2, -SCH3, -S(O)2СН3, циклопропила, циклобутила, оксетанила, морфолино и 1,1-диоксо-тиопиран-4-ила;
R6 и R9 образуют пятичленное или шестичленное гетероарильное или гетероциклическое кольцо, возможно замещенное одной или более группой R12;
R10 представляет собой Н, C1-C12 алкил, С2-С8 алкенил, С2-С8 алкинил, С6-С20 арил, С3-С12 карбоциклил, C2-C20 гетероциклил, C1-C20 гетероарил, -(C1-C12 алкилен)-(С3-С12 карбоциклил), -(C1-C12 алкилен)-(С2-С20 гетероциклил), -(C1-C12 алкилен)-С(=O)-(С2-С20 гетероциклил), -(C1-C12 алкилен)-(С6-С20 арил), -(С6-С20 арил)-(С1-С20 гетероарил), -(С6-С20 арил)-(С2-С20 гетероциклил), и -(C1-C12 алкилен)-(С1-С20 гетероарил), где алкил, алкенил, алкинил, алкилен, карбоциклил, гетероциклил, арил и гетероарил возможно замещены одной или более группами, независимо выбранными из F, Cl, Br, I, -СН3, -СН2СН3, -С(СН3)3, -CH2OH, -CH2CH2OH, -С(СН3)2OH, -CH2OCH3, -CN, -CH2F, -CHF2, -CF3, -CO2H, -СОСН3, -СОС(СН3)3, -CO2CH3, -CONH2, -CONHCH3, -CON(СН3)2, -С(СН3)2CONH2, -NO2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -N(СН3)С(СН3)2CONH2, -N(СН3)CH2CH2S(O)2СН3, =O, -ОН, -ОСН3, -S(O)2N(СН3)2, -SCH3, -S(O)2СН3, циклопропила, циклобутила, оксетанила, морфолино и 1,1-диоксо-тиопиран-4-ила; и
R11 представляет собой Н, F, Cl, Br, I, CN, -N(R5), -OR5, C1-C12 алкил, С2-C8 алкенил, С2-С8 алкинил, С6-С20 арил, С3-С12 карбоциклил, C2-C20 гетероциклил, C1-C20 гетероарил, -(C1-C12 алкилен)-(С3-С12 карбоциклил), -(C1-C12 алкилен)-(С2-С20 гетероциклил), -(C1-C12 алкилен)-С(=O)-(С2-С20 гетероциклил), -(C1-C12 алкилен)-(С6-С20 арил), и -(C1-C12 алкилен)-(С1-С20 гетероарил), где алкил, алкенил, алкинил, алкилен, карбоциклил, гетероциклил, арил и гетероарил возможно замещены одной или более группами, независимо выбранными из F, Cl, Br, I, -СН3, -СН2СН3, -С(СН3)3, -СН2ОН, -СН2СН2ОН, -С(СН3)2OH, -СН2ОСН3, -CN, -CH2F, -CHF2, -CF3, -СО2Н, -СОСН3, -СОС(СН3)3, -СО2СН3, -CONH2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NO2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -NHS(O)2CH3, -N(CH3)C(CH3)2CONH2, -N(СН3)CH2CH2S(O)2СН3, =O, -ОН, -ОСН3, -S(O)2N(CH3)2, -SCH3, -S(O)2СН3, циклопропила, циклобутила, оксетанила, морфолино и 1,1-диоксо-тиопиран-4-ила.
2. Соединение по п.1, где R6 и R9 образуют имидазолил, пиперидонил, пирролидинил или пиразолил.
3. Соединение по п.1, выбранное из группы, состоящей из:
9-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-9Н-пурин-6-амина,
4-амино-8-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)пиридо[2,3-d]пиримидин-5(8Н)-она,
7-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-7Н-пирроло[2,3-d]пиримидин-4-амина,
5-йод-7-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-7Н-пирроло[2,3-d]пиримидин-4-амина,
3-йод-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-4-амина,
3-метил-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-4-амина,
3-(4-амино-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-3-ил)проп-2-ин-1-ола,
3-(4-амино-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-3-ил)-5-фторфенола,
3-(1Н-индол-3-ил)-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-4-амина,
4-(4-амино-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-3-ил)-2-фторфенола,
N-(6-(4-амино-1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-3-ил)диметил[d]тиазол-2-ил)ацетамида,
1-((1-фенил-1Н-диметил[d]имидазол-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-6-амина,
9-((3-фенил-1Н-индол-2-ил)метил)-9Н-пурин-6-амина,
9-((3-фенилбензофуран-2-ил)метил)-9Н-пурин-6-амина,
1-((3-фенилбензо[b]тиофен-2-ил)метил)-1Н-пиразоло[3,4-d]пиримидин-4-амина,
9-((3-фенилбензо[b]тиофен-2-ил)метил)-9Н-пурин-6-амина и
9-((3-о-толилбензо[b]тиофен-2-ил)метил)-9Н-пурин-6-амина.
4. Фармацевтическая композиция, содержащая соединение по любому из пп.1-3 и фармацевтически приемлемый носитель, глидант, разбавитель или эксципиент.
5. Фармацевтическая композиция по п.5, дополнительно содержащая химиотерапевтическое средство.
6. Способ получения фармацевтической композиции, который включает комбинирование соединения по любому из пп.1-3 с фармацевтически приемлемым носителем.
7. Способ лечения заболевания или нарушения, при этом способ включает введение терапевтически эффективного количества соединения по любому из пп.1-3 пациенту с заболеванием или нарушением, выбранным из опухолей, иммунных заболеваний, сердечно-сосудистых заболеваний, вирусных инфекций, воспаления, нарушений метаболизма/эндокринных функций и неврологических заболеваний и опосредованных р110 дельта изоформой PI3 киназы.
8. Способ по п.7, где заболевание или нарушение представляет собой иммунное заболевание.
9. Способ по п.7, где заболевание или нарушение представляет собой системное и местное воспаление, артрит, воспаление, связанное с подавлением иммунитета, отторжение трансплантированных органов, аллергии, язвенный колит, болезнь Крона, дерматит, бронхиальную астма, системную красную волчанку, синдром Шегрена, рассеянный склероз, склеродермию/системный склероз, идиопатическую тромбоцитопеническую пурпуру (ITP), цитоплазматические антитела против нейтрофилов (ANCA), васкулит, хроническую обструктивную болезнь легких (ХОБЛ), псориаз.
10. Способ по п.7, где заболевание или нарушение представляет собой рак, выбранный из рака молочной железы, яичника, шейки матки, предстательной железы, яичка, мочеполовых путей, пищевода, гортани, глиобластомы, нейробластомы, желудка, кожи, кератоакантомы, легкого, плоскоклеточного рака, крупноклеточного рака, немелкоклеточной карциномы легкого (NSCLC), мелкоклеточного рака, аденокарциномы легких, костей, толстой кишки, аденомы, поджелудочной железы, аденокарциномы щитовидной железы, фолликулярного рака, недифференцированной карциномы, папиллярной карциномы, семиномы, меланомы, саркомы, рака мочевого пузыря, рака печени и желчных протоков, почечную карциному, рака поджелудочной железы, миелоидных нарушений, лимфомы, «волосатых» клеток, полости рта, носоглотки, глотки, губ, языка, рта, тонкой кишки, толстой и подвздошной кишок, толстой кишки, прямой кишки, мозга и центральной нервной системы, лимфомы Ходжкина, лейкемии, бронхов, щитовидной железы, печени и внутрипеченочных желчных протоков, гепатоцеллюлярного, желудка, глиомы/глиобластомы, рака эндометрия, меланомы, почек и почечной лоханки, мочевого пузыря, тела матки, шейки матки, множественной миеломы, острого миелобластного лейкоза, хронического лимфолейкоза, хронического миелолейкоза, лимфолейкоза, миелолейкоза, полости рта и глотки, неходжкинской лимфомы, меланомы и ворсинчатой аденомы толстой кишки.
11. Способ по п.7, где заболевание или нарушение представляет собой гемопоэтическое злокачественное новообразование, выбранное из лейкоза, неходжкинской лимфомы, диффузной крупноклеточной гемопоэтической лимфомы, фолликулярной лимфомы, лимфомы клеток мантийной зоны, хронического лимфоцитарного лейкоза (ХЛЛ), множественной миеломы, острого миелоидного лейкоза (AML) и миелоидного лейкоза (MCL).
12. Способ по п.7, дополнительно включающий введение дополнительного терапевтического средства, выбранного из химиотерапевтического агента, противовоспалительного средства, иммуномодулирующего средства, нейротропного фактора, средства для лечения сердечно-сосудистых заболеваний, средства для лечения заболеваний печени, противовирусного средства, средства для лечения заболеваний крови, средства для лечения диабета и средства для лечения иммунодефицитных состояний.
13. Набор для лечения состояний, опосредованных р110 дельта изоформой PI3 киназы, содержащий:
a) первую фармацевтическую композицию по п.4 и
b) инструкцию по применению.
14. Соединение по любому из пп.1-3 для применения в качестве лекарственного средства.
15. Применение соединения по любому из пп.1-3 для лечения заболевания или нарушения, выбранного из опухолей, иммунных заболеваний, сердечно-сосудистых заболеваний, вирусных инфекций, воспаления, нарушений метаболизма/эндокринных функций и неврологических заболеваний, и опосредованных р110 дельта изоформой PI3 киназы.
16. Соединение по любому из пп.1-3 для применения при лечении заболевания или нарушения, выбранного из опухолей, иммунных заболеваний, сердечно-сосудистых заболеваний, вирусных инфекций, воспаления, нарушений метаболизма/эндокринных функций и неврологических заболеваний, и опосредованных р110 дельта изоформой PI3 киназы.
17. Применение соединения по любому из пп.1-3 для производства лекарственного средства.
18. Применение по п.17, где лекарственное средство предназначено для лечения опухолей, иммунных заболеваний, сердечно-сосудистых заболеваний, вирусных инфекций, воспаления, нарушений метаболизма/эндокринных функций и неврологических заболеваний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441014P | 2011-02-09 | 2011-02-09 | |
US61/441,014 | 2011-02-09 | ||
PCT/EP2012/052090 WO2012107465A1 (en) | 2011-02-09 | 2012-02-08 | Heterocyclic compounds as pi3 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013138835A true RU2013138835A (ru) | 2015-03-20 |
Family
ID=45688453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013138835/04A RU2013138835A (ru) | 2011-02-09 | 2012-02-08 | Гетероциклические соединения в качестве ингибиторов pi3 киназы |
Country Status (10)
Country | Link |
---|---|
US (1) | US8653089B2 (ru) |
EP (1) | EP2673269A1 (ru) |
JP (1) | JP5766820B2 (ru) |
KR (1) | KR20130116358A (ru) |
CN (1) | CN103476767B (ru) |
BR (1) | BR112013020329A2 (ru) |
CA (1) | CA2825028A1 (ru) |
MX (1) | MX2013008822A (ru) |
RU (1) | RU2013138835A (ru) |
WO (1) | WO2012107465A1 (ru) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2530545T3 (es) | 2010-12-16 | 2015-03-03 | Hoffmann La Roche | Compuestos tricíclicos inhibidores de la PI3K y métodos de uso |
WO2013090725A1 (en) * | 2011-12-15 | 2013-06-20 | Philadelphia Health & Education Corporation | NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF |
US9493464B2 (en) * | 2012-02-29 | 2016-11-15 | The Scripps Research Institute | Wee1 degradation inhibitors |
US9737521B2 (en) | 2012-11-08 | 2017-08-22 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor |
GB201220157D0 (en) * | 2012-11-08 | 2012-12-26 | Selvita Sa | Substitute tricyclic benzimidazoles as kinase inhibitors |
WO2014081718A1 (en) | 2012-11-20 | 2014-05-30 | Genentech, Inc. | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
EP2941426B1 (en) | 2012-12-21 | 2018-06-13 | Gilead Calistoga LLC | Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors |
AU2013364070B2 (en) | 2012-12-21 | 2016-10-27 | Gilead Calistoga Llc | Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors |
NZ712453A (en) | 2013-03-15 | 2020-06-26 | Incyte Holdings Corp | Tricyclic heterocycles as bet protein inhibitors |
BR112015031475A2 (pt) | 2013-06-14 | 2017-07-25 | Gilead Sciences Inc | composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto. |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
BR112016003019A2 (pt) * | 2013-08-13 | 2017-09-12 | Univ Illinois | composto, composição farmacêutica, método para tratar câncer em um sujeito com necessidade do mesmo, e método para inibir uma desoxicitidina quinase |
JP6484555B2 (ja) * | 2013-08-29 | 2019-03-13 | 京都薬品工業株式会社 | 新規芳香族化合物およびその用途 |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
EA034972B1 (ru) | 2014-04-23 | 2020-04-13 | Инсайт Корпорейшн | 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet |
JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Betタンパク質阻害剤として用いるための三環式複素環化合物 |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN105566329B (zh) * | 2014-11-07 | 2019-02-12 | 温州医科大学 | 一种吡唑[5,6-d]并嘧啶类EGFR抑制剂及其抗肿瘤活性 |
KR102328921B1 (ko) * | 2014-12-11 | 2021-11-19 | 낫코 파마 리미티드 | 항암제로서 7-(몰포리닐)-2-(n-피페라지닐)-메틸티에노 [2,3-c] 피리딘 유도체 |
US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
WO2016134668A1 (en) * | 2015-02-28 | 2016-09-01 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
LT3277682T (lt) | 2015-03-30 | 2019-06-25 | Daiichi Sankyo Company, Limited | 6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių |
CA2989684A1 (en) | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
CN112409378A (zh) | 2015-09-08 | 2021-02-26 | 豪夫迈·罗氏有限公司 | 三环pi3k抑制剂化合物及其使用方法 |
US10590126B2 (en) | 2015-10-15 | 2020-03-17 | Thomas Jefferson University | Non-selective protease activated receptor 4 ALA120THR isoform antagonist |
GB201518456D0 (en) * | 2015-10-19 | 2015-12-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20240033293A (ko) | 2016-06-20 | 2024-03-12 | 인사이트 코포레이션 | Bet 저해제의 결정질 고체 형태 |
US10261071B2 (en) * | 2016-07-13 | 2019-04-16 | The United States Of America As Represented By The Secretary Of The Navy | Volatile organic compounds as diagnostic breath markers for pulmonary oxygen toxicity |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
KR102399639B1 (ko) | 2016-12-02 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
NZ754944A (en) * | 2016-12-07 | 2023-02-24 | Beigene Ltd | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors |
PL3679042T3 (pl) | 2017-09-08 | 2023-09-04 | Beigene, Ltd. | Pochodne imidazo[1,5-a]pirazyny jako inhibitory PI3Kdelta |
GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
WO2019243523A1 (en) * | 2018-06-21 | 2019-12-26 | Cellestia Biotech Ag | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts |
TW202019408A (zh) * | 2018-06-28 | 2020-06-01 | 美商永恒生物科技公司 | 稠合三環雜環化合物及其治療用途 |
CN112552314B (zh) * | 2018-08-24 | 2022-03-04 | 杭州阿诺生物医药科技有限公司 | Sting激动剂小分子抗肿瘤化合物及其应用 |
KR20210125471A (ko) | 2018-10-05 | 2021-10-18 | 안나푸르나 바이오, 인코포레이티드 | Apj 수용체 활성과 관련된 병태를 치료하기 위한 화합물 및 조성물 |
TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
CN110054558B (zh) * | 2019-05-16 | 2022-03-25 | 海门瑞一医药科技有限公司 | 一种1-三氟甲基环丙烷-1-甲酸的制备方法 |
TW202146416A (zh) * | 2019-12-11 | 2021-12-16 | 德商拜耳廠股份有限公司 | 吡唑并三𠯤 |
CN115485030A (zh) * | 2020-03-06 | 2022-12-16 | 拜耳公司 | 咪唑并三嗪通过抑制cdk12作用于癌症 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN117597344A (zh) | 2021-05-06 | 2024-02-23 | 拜耳公司 | 烷基酰胺取代的环状咪唑及其作为杀虫剂的用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
GB1570494A (en) | 1975-11-28 | 1980-07-02 | Ici Ltd | Thienopyrimidine derivatives and their use as pesticides |
JPS6216477A (ja) * | 1985-07-15 | 1987-01-24 | Maruishi Seiyaku Kk | 抗ウイルス活性を有する2−(4−ピリジルアミノメチル)−ベンズイミダゾ−ル誘導体 |
US4740230A (en) * | 1985-09-13 | 1988-04-26 | Idemitsu Kosan Company Limited | Triazine derivatives, and herbicides containing the derivatives as the effective component |
CA1279648C (en) * | 1986-07-11 | 1991-01-29 | Haruo Kuriyama | 2-(4-pyridylaminometyl)-benzimidazole derivatives having antiviral activity |
US4932998A (en) | 1986-09-30 | 1990-06-12 | Idemitsu Kosan Company Limited | Triazine derivatives, and herbicides comprising the same as the effective ingredient |
WO1988002368A1 (en) * | 1986-09-30 | 1988-04-07 | Idemitsu Kosan Company Limited | Triazine derivative, production thereof, and herbicide containing same as effective ingredient |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
SE0102315D0 (sv) * | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7138401B2 (en) | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | 2-aminopurine analogs having HSP90-inhibiting activity |
EP1678168B1 (en) * | 2003-10-24 | 2012-07-11 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
JP5213229B2 (ja) * | 2004-04-23 | 2013-06-19 | エグゼリクシス, インコーポレイテッド | キナーゼ調節因子および使用方法 |
JP2007277093A (ja) * | 2004-06-21 | 2007-10-25 | Astellas Pharma Inc | 三環系化合物 |
CA2575560A1 (en) | 2004-08-02 | 2006-02-23 | Smithkline Beecham Corporation | Chemical compounds |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
NZ567140A (en) | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
AU2007243457B2 (en) | 2006-04-26 | 2012-02-23 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
BRPI0710874A2 (pt) | 2006-04-26 | 2012-02-14 | Hoffmann La Roche | compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos |
MX2008013583A (es) * | 2006-04-26 | 2008-10-31 | Genentech Inc | Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen. |
PL2050749T3 (pl) * | 2006-08-08 | 2018-03-30 | Chugai Seiyaku Kabushiki Kaisha | Pochodna pirymidyny jako inhibitor pi3k i jej zastosowanie |
WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
ES2435430T3 (es) * | 2006-10-16 | 2013-12-19 | Thesan Pharmaceuticals, Inc. | Pirazolil tienopiridinas terapéuticas |
CL2007003520A1 (es) | 2006-12-07 | 2008-08-22 | Piramed Ltd Genentech Inc | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. |
JP5500990B2 (ja) | 2006-12-07 | 2014-05-21 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド3−キナーゼ阻害剤化合物及び使用方法 |
WO2008152394A1 (en) * | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
WO2009034386A1 (en) * | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
ES2537624T3 (es) * | 2007-10-26 | 2015-06-10 | F. Hoffmann-La Roche Ag | Derivados purina útiles como inhibidores de la quinasa PI3 |
GB0725218D0 (en) * | 2007-12-24 | 2008-02-06 | Syngenta Ltd | Chemical compounds |
EP3216793B1 (en) * | 2008-05-23 | 2019-03-27 | Wyeth LLC | Triazine compounds as p13 kinase and mtor inhibitors |
KR20130026364A (ko) | 2009-05-27 | 2013-03-13 | 제넨테크, 인크. | P110 델타에 대해 선택적인 비시클릭 피리미딘 pi3k 억제제 화합물 및 사용 방법 |
SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
UY33304A (es) * | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
-
2012
- 2012-02-08 JP JP2013552943A patent/JP5766820B2/ja not_active Expired - Fee Related
- 2012-02-08 RU RU2013138835/04A patent/RU2013138835A/ru not_active Application Discontinuation
- 2012-02-08 US US13/369,016 patent/US8653089B2/en not_active Expired - Fee Related
- 2012-02-08 CA CA2825028A patent/CA2825028A1/en not_active Abandoned
- 2012-02-08 KR KR1020137023000A patent/KR20130116358A/ko active IP Right Grant
- 2012-02-08 WO PCT/EP2012/052090 patent/WO2012107465A1/en active Application Filing
- 2012-02-08 BR BR112013020329A patent/BR112013020329A2/pt not_active IP Right Cessation
- 2012-02-08 MX MX2013008822A patent/MX2013008822A/es not_active Application Discontinuation
- 2012-02-08 EP EP12704739.7A patent/EP2673269A1/en not_active Withdrawn
- 2012-02-08 CN CN201280017361.6A patent/CN103476767B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2014508145A (ja) | 2014-04-03 |
KR20130116358A (ko) | 2013-10-23 |
CN103476767B (zh) | 2015-06-10 |
BR112013020329A2 (pt) | 2016-08-02 |
EP2673269A1 (en) | 2013-12-18 |
US8653089B2 (en) | 2014-02-18 |
US20120202785A1 (en) | 2012-08-09 |
MX2013008822A (es) | 2013-10-07 |
CN103476767A (zh) | 2013-12-25 |
CA2825028A1 (en) | 2012-08-16 |
JP5766820B2 (ja) | 2015-08-19 |
WO2012107465A1 (en) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013138835A (ru) | Гетероциклические соединения в качестве ингибиторов pi3 киназы | |
US11485745B2 (en) | Amido spirocyclic amide and sulfonamide derivatives | |
AU2017289418B2 (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
AU2018210770B2 (en) | Bicyclic compounds as allosteric SHP2 inhibitors | |
ES2360933T3 (es) | Derivados de heteroarilo condensados. | |
AU2006297120B2 (en) | Substituted pyrazole compounds | |
RU2014114973A (ru) | Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения | |
RU2014121074A (ru) | Соединения 8-фторфталазин-1(2н)-она в качестве ингибиторов тирозинкиназы брутона | |
JP5746172B2 (ja) | ホスホイノシチド3−キナーゼ阻害剤としての三環式複素環化合物 | |
RU2014153800A (ru) | Соединения 5-азаиндазола и способы их применения | |
RU2010154428A (ru) | Пуриновые соединения, ингибирующие рi3к и способы применения | |
RU2014106966A (ru) | Пиразоло[3,4-с]пиридины и способы их применения | |
US9458172B2 (en) | Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives | |
RU2016101548A (ru) | Соединения амидов гетероарилпиридона и азапиридона | |
JP2020505376A5 (ru) | ||
TR201811976T4 (tr) | Mek inhibitörleri olarak heterosiklil bileşikleri. | |
RU2013143747A (ru) | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения | |
AU2010343102A1 (en) | Type II Raf kinase inhibitors | |
RU2014121073A (ru) | Бициклические соединения пиперазина | |
US9586975B2 (en) | Macrocyclic salt-inducible kinase inhibitors | |
WO2013130943A1 (en) | Alkyl-and di-substituted amido-benzyl sulfonamide derivatives | |
KR20090038895A (ko) | 융합된 피리미도 화합물 | |
AU2014307437A1 (en) | Novel fused pyrimidine compound or salt thereof | |
RU2015108410A (ru) | Соединения диоксин- и оксазин[2,3-d]пиримидина в качестве ингибиторов фосфоинозитид-3-киназы и способы их применения | |
US20160024114A1 (en) | Macrocyclic rip2 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160617 |